Thanks Kelsee. They've added two events to the Q1 calendar since I last checked January 11. The Las Vegas Dialysis/CKD conference Feb 1-3 that you pointed out, and the BD Boston conference March 9. 

BearDownAZ 

Thanks for the reminder Kelsee. I made a short post a couple weeks back when this first appeared on their Q1 events. Here is the text from that post. Should be a good event.

--------------

One of the Q1 events is a Keystone Symposia (see event details below). Keystone Symposia are GREAT scientific meetings. Norm Wong presents on February 2nd discussing BET inhibitors in cardiovascular disease AND rheumatoid arthritis. It's been a while since we've heard from either Resverlogix or Zenith on their arthritis program. Hopefully that is a sign that the arthritis program is still alive and well.

Epigenetics and Human Disease: Progress from Mechanisms to Therapeutics

January 29—February 2, 2017

Sheraton Seattle Hotel, Seattle, Washington, USA

Thursday February 2

Norm Wong, Resverlogix Corporation, Canada 

Short Talk: Selective BET Inhibitors are Useful for Normalizing Inflammation Leading to Reduced Cardiovascular Disease (CVD) in Humans and in an Animal Model of Rheumatoid Arthritis

Also, in addition to yesterday's NR on the proteomic data from the Phase 1 CKD trial, there was a news release from November 17, 2016 on the favorable RVX-208 pharmacokinetic data in that trial. 

BearDownAZ 

Now that we've absorbed that exciting news release for the Phase 1 CKD trial, I thought it would be good to remind all of the imminent start to the Phase 2 CKD trial.

 At the October 2016 R&D day presentation, Dr. Kamyar Kalantar-Zadeh described the proposed Phase 2b BETonDialysis trial with an estimated launch early 2017. The proposed design is a sequential cross-over trial to evaluate the safety, tolerability, and efficacy of apabetalone (200 mg daily) in high-risk CKD patients on hemodialysis. Up to 30 CKD subjects on hemodialysis, double-blinded, placebo-controlled, cross-over after 2 week washout. Proposed primary endpoint is ALP reduction. 2 week screening, 6 week duration, 2 week washout, 6 week treatment, 2 week follow up.

At the 12/15/16 Corporate Update, they indicated that this Phase 2 BETonDialysis trial will launch early 2017, will be in the US, and added that the washout period will be longer (~6 wks instead of the 2 wks shown on the slide). They also indicated in a slide from the Corporate Update and from Biotech Showcase in January 2017 presentation:

1) Filed for a Type B Meeting early fall 2016

2) Completed Type B Meeting late fall 2016, face to face in Washington

3) Received positive feedback on trial design and positive instructions to enhance the program without affecting the IND filing timeline

4) New Cardio/Renal IND on track for Q1 2017

So getting that IND filed, seeing something appear on ClinicalTrials.gov, and getting a NR on trial launch are the next steps here, IMO.

GLTA,

BearDownAZ

Chicagoest,

As far as I know, the only MOA that Resverlogix has disclosed for how RVX-208 may mitigate neurodegenerative diseases such as Alzheimer's is related to the ability of RVX-208 to elevate apoAI and HDL. However, there may be a lot more going on behind the scenes that would offer additional MOAs. So yes, it is possible that RVX-208 could improve the function of Verubecestat, but it's hard to guess not knowing more about how RVX-208 works in the brain. RVX does have a neurodegenerative clinical advisory board, and a substudy of BETonMACE is related to some memory/Alzheimer's readouts.....so clearly RVX is not giving up on Alzheimer's yet.

http://www.prnewswire.com/news-releases/resverlogix-assert-trial-data-illustrates-potential-for-rvx-208-in-alzheimers-disease-114560869.html

https://www.resverlogix.com/upload/latest_news/81/01/2008-11-10_alzheimers_program_final.pdf

Great post San Fran. Thanks.